Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 26, 2021

Clover Biopharmaceuticals begins Covid-19 vaccine booster trial

The trial will analyse the safety and immunogenicity of the booster shot by enrolling healthy adults at several Brazilian sites.

Clover Biopharmaceuticals has begun a Phase II clinical trial to assess its Covid-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), as a heterologous booster shot in people who received an initial vaccine regimen.

Using its Trimer-Tag technology platform, the company developed the SCB-2019 antigen, which was merged with CpG 1018 advanced adjuvant of Dynavax and aluminum hydroxide (alum).

The double-blind, controlled, randomised, two-stage trial is sponsored by the Instituto D’Or de Pesquisa e Ensino (IDOR) and has received funding from the Bill & Melinda Gates Foundation.

It is also being backed by the Brazilian Ministry of Health.

The investigator-led trial will assess the safety and immunogenicity of a booster dose of the protein-based vaccine in almost 520 healthy adult subjects at multiple trial centres in Brazil.

Its first stage will analyse three vaccine formulations given as a booster shot almost six months after the initial vaccine regimen with AstraZeneca-Fiocruz’s recombinant Covid-19 shot.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

In the second stage, the immunogenicity and safety of a booster dose of the opted formulation of SCB-2019 will be analysed in people inoculated with two shots of either the CoronaVac vaccine or the AstraZeneca-Fiocruz vaccine.

The preliminary results from the trial are expected to be announced in the first half of next year.

Clover Biopharmaceuticals CEO Joshua Liang said: “We are excited to learn how our Covid-19 vaccine candidate performs as a booster dose for people previously vaccinated with either inactivated or adenovirus-vectored Covid-19 vaccines.

“SPECTRA trial data reported in September showed that vaccination with SCB-2019 (CpG 1018/Alum) in individuals previously infected by SARS-CoV-2 demonstrated a rapid and strong boosting effect on neutralising antibody titers, as well as a favourable safety profile, thus supporting the evaluation of our Covid-19 vaccine candidate as a potential booster vaccine.”

In June, Clover signed an advance purchase agreement with Gavi, the Vaccine Alliance, to deliver up to 414 million doses of the vaccine.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU